Contribute Try STAT+ Today

Frustrated by tepid sales and practical stumbling blocks, Regeneron and Sanofi are offering a huge discount on their treatment for bad cholesterol in exchange for a promise that health care’s biggest middleman will make it easier for patients to actually get the drug.

Starting in July, the two companies will sell their cholesterol-lowering drug Praluent, which carries a $14,600 list price, at roughly 60 percent off to clients of Express Scripts, the nation’s biggest pharmacy benefit manager. In exchange, Express Scripts will make their drug the only cholesterol-lowering injection available to the 25 million patients on its formulary, freezing out a rival therapy from Amgen. And, most important, Express Scripts will scrap the weeks of paperwork now required to approve a prescription, and implement a simple form that will allow doctors to get an immediate answer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.